Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing

Abstract Objective: A previous study by this group demonstrated the feasibility of RNA sequencing (RNAseq) technology for capturing disease biology of clear cell renal cell carcinoma (ccRCC), and presented initial results for carbonic anhydrase-9 (CA9) and tumor necrosis factor-α-induced protein-6 (TNFAIP6) as possible biomarkers of ccRCC (discovery set) [Eikrem et al. PLoS One 2016;11:e0149743]. To confirm these results, the previous study is expanded, and RNAseq data from additional matched ccRCC and normal renal biopsies are analyzed (confirmation set). Materials and methods: Two core biopsies from patients (n = 12) undergoing partial or full nephrectomy were obtained with a 16 g needle. RNA sequencing libraries were generated with the Illumina TruSeq® Access library preparation protocol. Comparative analysis was done using linear modeling (voom/Limma; R Bioconductor). Results: The formalin-fixed and paraffin-embedded discovery and confirmation data yielded 8957 and 11,047 detected transcripts, respectively. The two data sets shared 1193 of differentially expressed genes with each other. The average expression and the log2-fold changes of differentially expressed transcripts in both data sets correlated, with R² = .95 and R² = .94, respectively. Among transcripts with the highest fold changes were CA9, neuronal pentraxin-2 and uromodulin. Epithelial–mesenchymal transition was highlighted by differential expression of, for example, transforming growth factor-β1 and delta-like ligand-4. The diagnostic accuracy of CA9 was 100% and 93.9% when using the discovery set as the training set and the confirmation data as the test set, and vice versa, respectively. These data further support TNFAIP6 as a novel biomarker of ccRCC. TNFAIP6 had combined accuracy of 98.5% in the two data sets. Conclusions: This study provides confirmatory data on the potential use of CA9 and TNFAIP6 as biomarkers of ccRCC. Thus, next-generation sequencing expands the clinical application of tissue analyses.

[1]  Michael D. Johnson,et al.  Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process , 2015, Breast Cancer Research and Treatment.

[2]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[3]  Z. Cai,et al.  Increased Expression of Pregnancy Up-Regulated Non-Ubiquitous Calmodulin Kinase Is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma , 2013, PloS one.

[4]  M. Rydzanicz,et al.  Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. , 2013, Cancer letters.

[5]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[6]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[7]  J. Tostain,et al.  Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. , 2008, The Journal of urology.

[8]  U. Harmenberg,et al.  Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden , 2015, BioMed research international.

[9]  Jing Chen,et al.  Integrated Profiling of MicroRNAs and mRNAs: MicroRNAs Located on Xq27.3 Associate with Clear Cell Renal Cell Carcinoma , 2010, PloS one.

[10]  Y. Okada,et al.  Expression of TNF‐α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas , 2015, International journal of cancer.

[11]  E. Maher Genomics and epigenomics of renal cell carcinoma. , 2013, Seminars in cancer biology.

[12]  N. Dimitrova,et al.  Identification of a novel PARP14‐TFE3 gene fusion from 10‐year‐old FFPE tissue by RNA‐seq , 2015, Genes, chromosomes & cancer.

[13]  S. Perner,et al.  Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma , 2016, Molecular Cancer.

[14]  J. Tostain,et al.  Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. , 2010, European journal of cancer.

[15]  A. Phillips,et al.  Tumour necrosis factor-stimulated gene (TSG)-6 controls epithelial-mesenchymal transition of proximal tubular epithelial cells. , 2011, The international journal of biochemistry & cell biology.

[16]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[17]  Maqc Consortium The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[18]  Ximing J. Yang,et al.  Predictors of response to targeted therapy in renal cell carcinoma. , 2012, Archives of pathology & laboratory medicine.

[19]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Signoretti,et al.  Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity , 2009, Clinical Proteomics.

[21]  D. Radisky,et al.  Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. , 2014, Cancer research.

[22]  Mala Sinha,et al.  Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma , 2010, PloS one.

[23]  E. Oosterwijk Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment. , 2014, Sub-cellular biochemistry.

[24]  B. Ljungberg,et al.  Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. , 2011, European urology.

[25]  Sun Il Kim,et al.  Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma , 2016, Scandinavian journal of urology.

[26]  D. Gisselsson,et al.  Gene fusion detection in formalin-fixed paraffin-embedded benign fibrous histiocytomas using fluorescence in situ hybridization and RNA sequencing , 2015, Laboratory Investigation.

[27]  Ming Zhou,et al.  Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. , 2010, Urology.

[28]  J. Adolfsson,et al.  Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the National Swedish Kidney Cancer Register , 2014, Scandinavian journal of urology.

[29]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[30]  Andreas Scherer,et al.  Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development , 2016, PloS one.